|
Bentrem, D; Dardes, R; Liu, H et al. (2001) Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen. Endocrinology 142:838-46
|
|
Jordan, V C (2001) Selective estrogen receptor modulation: a personal perspective. Cancer Res 61:5683-7
|
|
MacGregor Schafer, J; Liu, H; Levenson, A S et al. (2001) Estrogen receptor alpha mediated induction of the transforming growth factor alpha gene by estradiol and 4-hydroxytamoxifen in MDA-MB-231 breast cancer cells. J Steroid Biochem Mol Biol 78:41-50
|
|
MacGregor Schafer, J; Liu, H; Bentrem, D J et al. (2000) Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351. Cancer Res 60:5097-105
|
|
Schafer, J M; Lee, E S; O'Regan, R M et al. (2000) Rapid development of tamoxifen-stimulated mutant p53 breast tumors (T47D) in athymic mice. Clin Cancer Res 6:4373-80
|
|
Schafer, J I; Liu, H; Tonetti, D A et al. (1999) The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor. Cancer Res 59:4308-13
|
|
Levenson, A S; Svoboda, K M; Kwaan, H C et al. (1998) Agonist activity of antiestrogen-receptor complexes to regulate urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) endogenous gene expression in breast cancer cells. Cancer Lett 125:215-20
|
|
Levenson, A S; Jordan, V C (1998) The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor. Cancer Res 58:1872-5
|
|
MacGregor, J I; Jordan, V C (1998) Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 50:151-96
|
|
Levenson, A S; Kwaan, H C; Svoboda, K M et al. (1998) Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor. Br J Cancer 78:88-95
|
Showing the most recent 10 out of 25 publications
